Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | gastric inhibitory polypeptide receptor | Starlite/ChEMBL | References |
Homo sapiens | glucagon receptor | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Loa Loa (eye worm) | pigment dispersing factor receptor c | gastric inhibitory polypeptide receptor | 466 aa | 425 aa | 24.7 % |
Loa Loa (eye worm) | pigment dispersing factor receptor c | glucagon receptor | 477 aa | 457 aa | 25.4 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | hypothetical protein | 0.012 | 0.1196 | 0.1196 |
Brugia malayi | latrophilin 2 splice variant baaae | 0.0082 | 0.0262 | 0.0262 |
Loa Loa (eye worm) | hypothetical protein | 0.0244 | 0.4233 | 0.4233 |
Toxoplasma gondii | calcium binding egf domain-containing protein | 0.008 | 0.0197 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0082 | 0.0262 | 0.0574 |
Schistosoma mansoni | subfamily M12A unassigned peptidase (M12 family) | 0.0258 | 0.4566 | 1 |
Echinococcus granulosus | Tolloid protein 1 | 0.0258 | 0.4566 | 1 |
Brugia malayi | Calcitonin receptor-like protein seb-1 | 0.012 | 0.1196 | 0.1196 |
Loa Loa (eye worm) | pigment dispersing factor receptor c | 0.012 | 0.1196 | 0.1196 |
Brugia malayi | Fibulin-1 precursor | 0.008 | 0.0197 | 0.0197 |
Loa Loa (eye worm) | hypothetical protein | 0.0082 | 0.0262 | 0.0262 |
Loa Loa (eye worm) | bone morphogenetic protein 1b | 0.0258 | 0.4566 | 0.4566 |
Onchocerca volvulus | Arrow homolog | 0.0072 | 0 | 0.5 |
Loa Loa (eye worm) | DPY-31 protein | 0.048 | 1 | 1 |
Brugia malayi | Calcium binding EGF domain containing protein | 0.008 | 0.0197 | 0.0197 |
Loa Loa (eye worm) | hypothetical protein | 0.0108 | 0.0892 | 0.0892 |
Echinococcus multilocularis | Tolloid protein 1 | 0.0258 | 0.4566 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.008 | 0.0197 | 0.0197 |
Brugia malayi | Corticotropin releasing factor receptor 2 precursor, putative | 0.012 | 0.1196 | 0.1196 |
Loa Loa (eye worm) | AStacin protease | 0.0158 | 0.2116 | 0.2116 |
Toxoplasma gondii | calcium binding egf domain-containing protein | 0.008 | 0.0197 | 0.5 |
Loa Loa (eye worm) | multiple epidermal growth factor-like domains 6 | 0.008 | 0.0197 | 0.0197 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 1.01 nM | Displacement of [125]glucagon from human glucagon receptor expressed in CHO cells | ChEMBL. | 17126016 |
IC50 (binding) | = 1.01 nM | Displacement of [125]glucagon from human glucagon receptor expressed in CHO cells | ChEMBL. | 17126016 |
IC50 (functional) | = 18 nM | Antagonist activity at human glucagon receptor transfected in CHO cells assessed as inhibition of glucagon-induced cAMP accumulation | ChEMBL. | 17126016 |
IC50 (functional) | = 18 nM | Antagonist activity at human glucagon receptor transfected in CHO cells assessed as inhibition of glucagon-induced cAMP accumulation | ChEMBL. | 17126016 |
IC50 (binding) | = 216 nM | Displacement of [125]glucagon from human glucagon receptor expressed in CHO cells | ChEMBL. | 17126016 |
IC50 (binding) | = 216 nM | Displacement of [125]glucagon from human glucagon receptor expressed in CHO cells | ChEMBL. | 17126016 |
IC50 (functional) | = 435 nM | Antagonist activity at human GIP receptor transfected in CHO cells assessed as inhibition of glucagon-induced cAMP accumulation | ChEMBL. | 17126016 |
IC50 (functional) | = 435 nM | Antagonist activity at human GIP receptor transfected in CHO cells assessed as inhibition of glucagon-induced cAMP accumulation | ChEMBL. | 17126016 |
IC50 (functional) | = 795 nM | Antagonist activity at human glucagon receptor transfected in CHO cells assessed as inhibition of glucagon-induced cAMP accumulation | ChEMBL. | 17126016 |
IC50 (functional) | = 795 nM | Antagonist activity at human glucagon receptor transfected in CHO cells assessed as inhibition of glucagon-induced cAMP accumulation | ChEMBL. | 17126016 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.